The bark giving diabetes therapy some bite: the SGLT inhibitors Sally M. Marshall Editorial 22 August 2018 Pages: 2075 - 2078
Development of SGLT1 and SGLT2 inhibitors Timo RiegVolker Vallon Review 22 August 2018 Pages: 2079 - 2086
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2 Chiara GhezziDonald D. F. LooErnest M. Wright Review Open access 22 August 2018 Pages: 2087 - 2097
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure Merlin C. ThomasDavid Z. I. Cherney Review 22 August 2018 Pages: 2098 - 2107
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review Subodh VermaJohn J. V. McMurray Review 22 August 2018 Pages: 2108 - 2117
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits Beatrice C. LupsaSilvio E. Inzucchi Review 22 August 2018 Pages: 2118 - 2125
SGLT inhibitor adjunct therapy in type 1 diabetes Rory J. McCrimmonRobert R. Henry Review Open access 22 August 2018 Pages: 2126 - 2133
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases Christoph WannerNikolaus Marx Review 22 August 2018 Pages: 2134 - 2139
Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events Toshiaki OhkumaSanne A. E. PetersMark Woodward ARTICLE Open access 20 July 2018 Pages: 2140 - 2154
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial Naveed SattarDavid FitchettBernard Zinman Article Open access 31 July 2018 Pages: 2155 - 2163
Gluten intake and risk of type 2 diabetes in three large prospective cohort studies of US men and women Geng ZongBenjamin LebwohlQi Sun Article 03 August 2018 Pages: 2164 - 2173
Genome-wide association study of coronary artery disease among individuals with diabetes: the UK Biobank Tove FallStefan GustafssonErik Ingelsson Short Communication Open access 12 July 2018 Pages: 2174 - 2179
Identification of a missense variant in the WFS1 gene that causes a mild form of Wolfram syndrome and is associated with risk for type 2 diabetes in Ashkenazi Jewish individuals Vikas BansalBernhard O. BoehmAriel Darvasi Article 16 July 2018 Pages: 2180 - 2188
Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome Manabu KondoKatsuya TanabeYukio Tanizawa Article 28 July 2018 Pages: 2189 - 2201
MANF protects human pancreatic beta cells against stress-induced cell death Elina HakonenVikash ChandraTimo Otonkoski Article Open access 21 July 2018 Pages: 2202 - 2214
Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice Andrew T. TemplinDaniel T. MeierRebecca L. Hull Article 25 July 2018 Pages: 2215 - 2224
Programming of central and peripheral insulin resistance by low birthweight and postnatal catch-up growth in male mice Lindsey M. BerendsLaura DeardenSusan E. Ozanne Article Open access 24 July 2018 Pages: 2225 - 2234
A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes Md Abdul Hye KhanLauren KolbJohn D. Imig Article 21 July 2018 Pages: 2235 - 2246
More work is needed to better understand diabetes distress as a predictor of all-cause mortality in type 2 diabetes Nanna LindekildeFrans Pouwer Letter 14 August 2018 Pages: 2247 - 2248